Peptide Schedule
SS-31 (Elamipretide)4 residuesRYKFEach bubble = one amino acid. Size = residue mass. Color = chemical class.SS-31 (Elamipretide)
Benefits
About SS-31 (Elamipretide)
SS-31 (Elamipretide) is a mitochondria-targeted peptide that binds to cardiolipin on the inner mitochondrial membrane. Cardiolipin is essential for electron transport chain efficiency, and its oxidation is a key driver of aging. By stabilizing cardiolipin, SS-31 reduces reactive oxygen species (ROS) production at the source, improves ATP generation, and protects against mitochondrial dysfunction.
Who Should Consider SS-31 (Elamipretide)
- Adults with age-related mitochondrial dysfunction seeking to restore cellular energy
- Patients with Barth syndrome (FDA accelerated approval granted for this indication)
- Individuals with primary mitochondrial myopathy experiencing exercise intolerance
- Older adults with declining cardiac function related to mitochondrial impairment
- Patients with heart failure with preserved ejection fraction (HFpEF) under clinical investigation
- Adults interested in longevity interventions targeting the root cause of cellular aging
How SS-31 (Elamipretide) Works
SS-31 (elamipretide) is a cell-permeable, water-soluble tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2. Its alternating aromatic-cationic motif allows it to cross cell membranes without relying on mitochondrial membrane potential and concentrate more than 1,000-fold within mitochondria. Once inside, SS-31 selectively binds to cardiolipin, an anionic phospholipid found exclusively on the inner mitochondrial membrane. Cardiolipin anchors cytochrome c to the membrane and is required for proper electron transport chain (ETC) function. When cardiolipin becomes oxidized — a hallmark of aging and disease — cristae structure collapses, electron transfer between complexes III and IV slows, electrons leak to form superoxide, and ATP output drops. By binding cardiolipin, SS-31 prevents its peroxidation, stabilizes cristae architecture, and restores normal electron flow through the ETC. This reduces reactive oxygen species (ROS) at the point of generation rather than scavenging them after the fact. The downstream result is improved ATP synthesis, preserved mitochondrial membrane potential, and inhibition of cytochrome c release — blocking a key trigger of intrinsic apoptosis. In preclinical models, SS-31 has reversed age-related declines in cardiac function, improved renal filtration, restored skeletal muscle performance, and protected neurons from ischemia-reperfusion injury. In humans, 40 mg/day subcutaneous dosing has been studied in Barth syndrome (TAZPOWER trial), primary mitochondrial myopathy, and heart failure with preserved ejection fraction.
What to Expect
SS-31 begins accumulating in mitochondrial membranes. Cardiolipin stabilization starts at the molecular level. Most users notice no outward changes yet. Injection site reactions (redness, mild soreness) are the most common early experience.
Mitochondrial ETC efficiency begins to improve. Some individuals report subtle increases in baseline energy and reduced fatigue during daily activities. ROS production at the inner membrane decreases measurably in preclinical models at this timepoint.
Clinical trial data shows measurable improvements in 6-minute walk test distance and reduced fatigue scores in Barth syndrome patients during this window. Users may notice improved exercise tolerance, better recovery from physical exertion, and more consistent energy throughout the day.
Continued improvement in mitochondrial function. Cardiac parameters such as stroke volume and cardiac output showed improvement in open-label extension studies. Skeletal muscle strength and endurance gains become more noticeable.
Long-term open-label data (up to 168 weeks in TAZPOWER) showed sustained improvements in cardiac and functional outcomes. Protocol duration beyond 12 weeks should be guided by a physician. Long-term safety beyond clinical trial settings is not fully established.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 500mcg | Daily |
| Moderate | 1mg | Daily |
| Aggressive | 2mg | Daily |
Note: Targets inner mitochondrial membrane cardiolipin. Reduces ROS production. Investigated for Barth syndrome and age-related mitochondrial dysfunction.
Pharmacokinetics
Source: Plasma elimination half-life of ~4 hours after subcutaneous administration in human clinical trials (PMID 29440564)
Loading the interactive decay curve.
Side Effects
Generally well-tolerated. Injection site reactions. Under clinical investigation — long-term safety profile still being established.
Contraindications
- Pregnancy or breastfeeding — no reproductive safety data available; contraindicated in these populations
- Active malignancy or history of cancer — effects on tumor cell mitochondria not studied
- Severe cardiac conduction abnormalities — these patients were excluded from clinical trials; safety not established
- Known hypersensitivity to elamipretide or any formulation excipients
- Children under 30 kg body weight — FDA-approved dosing is for patients weighing at least 30 kg
- Severe renal impairment — SS-31 is renally excreted; clearance may be significantly reduced
Drug Interactions
- Anthracycline chemotherapeutics (doxorubicin, daunorubicin) — SS-31 may mask early signs of cardiotoxicity by protecting mitochondria; monitor cardiac function closely if co-administered
- Other mitochondrial-targeted compounds (MitoQ, CoQ10, idebenone) — no formal interaction studies; theoretical additive effects on mitochondrial membrane dynamics
- Immunosuppressants (cyclosporine A) — cyclosporine inhibits mitochondrial permeability transition pore opening, which overlaps with SS-31 mechanism; potential for unpredictable combined effects
- Insulin and oral hypoglycemics — while SS-31 does not directly affect glucose metabolism, improved mitochondrial function may alter insulin sensitivity; monitor blood glucose
- Anticoagulants — no known pharmacokinetic interaction, but as with all subcutaneous injectables, monitor for injection site bruising
Molecular Profile
Related Peptides
References
- Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential (Int J Mol Sci 2025)Review
- Mitochondrial protein interaction mapping of SS-31 (PNAS 2020)PubMed 32571916
- A phase 2/3 randomized clinical trial to evaluate elamipretide in Barth syndrome — TAZPOWER (Genet Med 2021)PubMed 33077895
- Long-term efficacy and safety of elamipretide in Barth syndrome: 168-week open-label extension results of TAZPOWER (Genet Med 2024)PubMed 38602181
- Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy (Neurology 2018)PubMed 29440564
- Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice (eLife 2020)PubMed 32648542
- ELZURA (elamipretide) injection FDA Prescribing InformationFDA Label